Douglas T. Sheehy

2018 - Aimmune Therapeutics

In 2018, Douglas T. Sheehy earned a total compensation of $3.2M as General Counsel and Secretary at Aimmune Therapeutics, a 87% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$165,000
Option Awards$1,600,335
Salary$372,883
Stock Awards$1,107,275
Other$2,000
Total$3,247,493

Sheehy received $1.6M in option awards, accounting for 49% of the total pay in 2018.

Sheehy also received $165K in non-equity incentive plan, $372.9K in salary, $1.1M in stock awards and $2K in other compensation.

Rankings

In 2018, Douglas T. Sheehy's compensation ranked 3,546th out of 14,244 executives tracked by ExecPay. In other words, Sheehy earned more than 75.1% of executives.

ClassificationRankingPercentile
All
3,546
out of 14,244
75th
Division
Manufacturing
1,310
out of 5,759
77th
Major group
Chemicals And Allied Products
459
out of 2,122
78th
Industry group
Drugs
378
out of 1,811
79th
Industry
Pharmaceutical Preparations
291
out of 1,385
79th
Source: SEC filing on April 10, 2019.

Sheehy's colleagues

We found five more compensation records of executives who worked with Douglas T. Sheehy at Aimmune Therapeutics in 2018.

2018

Jayson Dallas

Aimmune Therapeutics

Chief Executive Officer

2018

Daniel Adelman

Aimmune Therapeutics

Chief Medical Officer

2018

Eric Bjerkholt

Aimmune Therapeutics

Chief Financial Officer

2018

Stephen Dilly

Aimmune Therapeutics

Chief Executive Officer

2018

Susan Barrowcliffe

Aimmune Therapeutics

General Manager, Europe

News

You may also like